Streetbeat News

Analyst Ratings

CAH

TD Cowen analyst Charles Rhyee maintains a Market Perform rating on Cardinal Health (NYSE:CAH) and raises the price target from $88 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:40 pm

DLO

DLocal Limited (NASDAQ:DLO) reported better-than-expected Q2 financial results and reaffirmed its full-year guidance, leading to a surge in its stock price. Q2 revenue increased 59% YoY to $161.1 million, beating the consensus estimate of $151.18 million. The company also reported quarterly earnings of 15 cents per share, surpassing estimates of 13 cents per share. Following the announcement, Susquehanna analyst James Friedman maintained a Positive rating for DLocal and raised the price target from $18 to $24.

Portfolio Pulse from Adam Eckert

August 16, 2023 | 1:39 pm

OXY

Roth MKM analyst Leo Mariani has reiterated a Neutral rating on Occidental Petroleum (NYSE:OXY) and maintained a $60 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:38 pm

IHS

TD Cowen analyst Gregory Williams maintains an Outperform rating on IHS Holding (NYSE:IHS) but has lowered the price target from $29 to $26.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:37 pm

ZIM

Jefferies analyst Omar Nokta has reiterated a 'Hold' rating on ZIM Integrated Shipping (NYSE:ZIM) and maintained a price target of $13.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:36 pm

FRLN

Stifel analyst Dae Gon Ha maintains a 'Hold' rating on Freeline Therapeutics (NASDAQ:FRLN) and raises the price target from $3 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 1:35 pm

LPCN

Zacks Small-Cap Research has set a $40 price valuation for Lipocine Inc. (LPCN).

Portfolio Pulse from Happy Mohamed

August 16, 2023 | 1:35 pm

LUCD

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:33 pm

CLDX

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a $54 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:32 pm

CLNN

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Clene (NASDAQ:CLNN) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 1:31 pm